CanSino Biologics Inc. (CASBF)
CanSino Biologics Inc.
401-420, Biomedical Park
4th Floor 185 South Avenue TEDA West District
Tianjin 300457
China
86 022 5821 3600
https://www.cansinotech.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1,494
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Xuefeng Yu Ph.D. | Co-Founder, Executive Chairman, CEO & GM | N/D | N/D | 1965 |
| Dr. Tao Zhu Ph.D. | Co-Founder, Deputy GM, Chief Scientific Officer & Executive Director | N/D | N/D | 1974 |
| Dr. Dongxu Qiu MBA, Ph.D. | Co-Founder, Executive VP, Deputy GM & Executive Director | N/D | N/D | 1961 |
| Dr. Shou-Bai Chao Ph.D. | COO, Deputy GM & Executive Director | N/D | N/D | 1964 |
| Ms. Jing Wang | Chief Commercial Officer, Deputy GM & Executive Director | N/D | N/D | 1981 |
| Mr. Chunlin Xin | Senior Director of New Technology Department | N/D | N/D | N/D |
| Mr. Yonghui Wu | Vice President of Marketing | N/D | N/D | N/D |
| Mr. Jin Cui | Board Secretary | N/D | N/D | 1987 |
| Mr. Ming King Chiu FCIS, FCS | Joint Company Secretary | N/D | N/D | 1977 |
Descripción
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Gestión corporativa
La calificación ISS Governance QuickScore de CanSino Biologics Inc. a partir del 29 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 4; Junta: 7; Derechos del accionista: 9; Compensación: 3.
